U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. About FDA
  3. Performance Data
  4. FDA-TRACK: Agency-wide Program Performance
  5. FDA-TRACK: Office of the Chief Medical Officer - Office of Combination Products Dashboard
  1. FDA-TRACK: Agency-wide Program Performance

FDA-TRACK: Office of the Chief Medical Officer - Office of Combination Products Dashboard

Office of Clinical Policy and Programs
FDA-TRACK Home
 

On this page:

The Office of Combination Products (OCP) serves as a focal point for combination product (drug-device, biologic-device, drug-biologic, or drug-device-biologic products) issues for agency reviewers and industry. The office is responsible for ensuring the prompt assignment of combination products (drug-device, biologic-device, drug-biologic, or drug-device-biologic products) to FDA Centers, the timely and effective premarket review of such combination products, and consistent and appropriate postmarket regulation of these products. Explore the progress OCP is making towards its performance goals below.

I. Request for Formal Designation (RFD) Processing Measures

II. Informal Requests of Product Designation Processing Measures

Download OCMO OCP Dataset

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time.

Sign up to receive FDA-TRACK updates

Get regular FDA email updates delivered on this topic to your inbox.

Back to Top